CN113813260A - Use of roxasistat for relieving ischemic stroke-mediated synaptic injury - Google Patents
Use of roxasistat for relieving ischemic stroke-mediated synaptic injury Download PDFInfo
- Publication number
- CN113813260A CN113813260A CN202111323576.8A CN202111323576A CN113813260A CN 113813260 A CN113813260 A CN 113813260A CN 202111323576 A CN202111323576 A CN 202111323576A CN 113813260 A CN113813260 A CN 113813260A
- Authority
- CN
- China
- Prior art keywords
- reperfusion
- roxasistat
- ischemic stroke
- injury
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006378 damage Effects 0.000 title claims abstract description 17
- 230000001404 mediated effect Effects 0.000 title claims abstract description 14
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 13
- 208000014674 injury Diseases 0.000 title claims abstract description 13
- 230000000946 synaptic effect Effects 0.000 title claims abstract description 12
- 208000032382 Ischaemic stroke Diseases 0.000 title abstract description 23
- 230000010410 reperfusion Effects 0.000 claims abstract description 21
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 206010008118 cerebral infarction Diseases 0.000 abstract description 11
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000003956 synaptic plasticity Effects 0.000 abstract description 2
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 206010063837 Reperfusion injury Diseases 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002033 PVDF binder Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 9
- 210000000269 carotid artery external Anatomy 0.000 description 8
- 210000004004 carotid artery internal Anatomy 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 6
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000047174 Disks Large Homolog 4 Human genes 0.000 description 4
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 4
- 101000944251 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Calcium/calmodulin-dependent protein kinase cmkA Proteins 0.000 description 4
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 101150069842 dlg4 gene Proteins 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 210000003520 dendritic spine Anatomy 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 210000002763 pyramidal cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229940113151 HIF prolyl hydroxylase inhibitor Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004697 synapse damage Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000037868 anemia in chronic kidney disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000018511 hepcidin Human genes 0.000 description 1
- 108060003558 hepcidin Proteins 0.000 description 1
- 229940066919 hepcidin Drugs 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000008625 synaptic signaling Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides application of roxasistat in medicines for treating cerebral arterial thrombosis reperfusion-mediated synaptic injury. The roxasistat has a neuroprotective effect on cerebral ischemia-reperfusion therapy, and can effectively relieve synaptic plasticity injury mediated by ischemic stroke. Is expected to become a medicament for clinically treating cerebral arterial thrombosis reperfusion-mediated synaptic injury.
Description
Technical Field
The invention belongs to the field of new application of medicines, particularly relates to application of roxasistat in relieving cerebral ischemic stroke-mediated synaptic injury, and particularly relates to a nerve protection effect of roxasistat after cerebral ischemia reperfusion to relieve synaptic injury.
Background
Ischemic stroke is a disease that seriously endangers human health. The treatment means is mainly to implement thrombolytic therapy within an effective time window and to recover blood as soon as possible to prevent the ischemic region from spreading. Once the effective time window is exceeded, irreversible damage and even death of brain cells can result, which is life threatening and results in ischemic stroke reperfusion injury. At present, calcium channel antagonists, EAA antagonists and the like are mainly used clinically for resisting cerebral ischemic injury, but the treatment effect is poor.
After cerebral ischemia occurs, the damaged area of the brain expands in a gradient manner from the center of the damage to the periphery. As cerebral blood flow continues to decline, nervous system activity is inhibited and subsequent metabolic activity is affected. At the same time, the relevant signal transduction pathways that are activated trigger a series of events, such as: oxidative inflammatory reaction, apoptosis, etc. Under certain external stimuli or pathological conditions, the structure and density of dendritic spines are significantly altered, and remodeling of synaptic signaling may be activated thereby, controlling the brain's functions of learning, memory, cognition and motor coordination. After cerebral ischemia for 20min, the dendritic spine is changed in shape and reduced in number, resulting in failure of nerve conduction function, which indicates that neuron death and dendritic spine deletion are major nerve injuries caused by cerebral ischemia.
Rosemastat is an oral hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by the cooperation of Fabo and Asricon in China, which is approved for the treatment of anemia in CKD dialysis patients, including hemodialysis and peritoneal dialysis patients. The roxasistat can activate the transcription of related genes by stabilizing HIF, inhibiting the degradation of the HIF, generating corresponding physiological response, moderately increasing the concentration of erythropoietin, improving the sensitivity of Erythropoietin (EPO) receptors, coordinating the generation of red blood cells, reducing the level of hepcidin, increasing the content and activity of transferrin receptors and promoting the absorption and utilization of iron.
The structural formula of the roxasistat is shown as follows:
disclosure of Invention
The invention provides application of roxasistat in drugs for treating cerebral arterial thrombosis reperfusion-mediated synaptic injury. Solves the problem of synapse damage in the reperfusion therapy of iron-deficiency cerebral apoplexy in the prior art.
The technical scheme of the invention is realized as follows:
application of roxasistat in medicines for treating cerebral arterial thrombosis reperfusion-mediated synaptic injury.
Compared with the prior art, the invention has the following beneficial effects:
the roxasistat can improve the perfusion-mediated synaptic injury of ischemic stroke. Is expected to become clinically used for treating and improving the synapse damage caused by the ischemic stroke perfusion treatment.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.
FIG. 1-A is a graph of the body weight change before and after treatment of Rosemastat with ischemic stroke reperfusion injury;
FIG. 1-B is a graph of TTC staining of cerebral infarct volume after treatment of reperfusion injury in ischemic stroke by Rosxastat;
FIG. 1-C comparative graph of analysis of cerebral infarction volume after treatment of reperfusion injury by Rosxastat in ischemic stroke;
FIG. 1-graph of rat mortality following treatment of ischemic stroke reperfusion injury with Rosesarta;
FIG. 2-A is a graph of HE staining of brain histopathology following treatment of ischemic stroke reperfusion injury with Rosxastat;
FIG. 2-B is a graph of the rate of necrotic cells in the cortical region following treatment of reperfusion injury from stroke with ischemia;
FIG. 2-C is a graph of the rate of necrotic cells in the hippocampal region following treatment of reperfusion injury by Rossastat;
FIG. 2-graph of hippocampal CA1 zone pyramidal cell layer thickness following treatment of ischemic stroke reperfusion injury with Rosesartal;
FIG. 2-E graph of hippocampal CA2 zone pyramidal cell layer thickness after treatment of ischemic stroke reperfusion injury by Rosesarta;
FIG. 2-graph of Hippocampus CA3 zone pyramidal cell layer thickness after treatment of ischemic stroke reperfusion injury with Rosesartal;
FIG. 3-A shows an electrophoretogram of HIF-1. alpha. protein after treatment of reperfusion with Rosxastat in ischemic stroke;
FIG. 3-B is a graph comparing HIF-1 α expression levels after treatment of stroke with rospastat;
FIG. 3-C shows an electrophoretogram of VEGF protein after treatment of reperfusion with Rosxastat in ischemic stroke;
FIG. 3-graph comparing VEGF expression levels after treatment of ischemic stroke reperfusion with Rosxastat;
FIG. 4-A shows the protein electrophoresis patterns of CaMK II, PSD95 and CRBE after treatment of reperfusion of stroke with rospashead;
FIG. 4-B is a graph comparing the expression levels of CaMK II after reperfusion therapy of stroke with rosloxacin;
FIG. 4-C is a graph comparing the expression of PSD95 after treatment of Rosxastat with reperfusion of ischemic stroke;
FIG. 4-graph comparing CRBE expression levels after treatment of reperfusion with Rosesarta;
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
This example demonstrates the use of rosxastat in the treatment of cerebral arterial ischemic reperfusion-mediated synaptic injury.
1. Laboratory animal handling and grouping
Uniformly dividing 75 SD rats into 5 groups by using a random digital table method, wherein each group comprises 15 rats, constructing an ischemic stroke reperfusion model by using a middle cerebral artery embolization method, treating the rats with different doses of Rosemastat, and then taking brain tissues for detection: (1)2, 3, 5-triphenyltetrazolium chloride (TTC) staining to evaluate the cerebral infarction volume; (2) daily body weight and mortality of rats were monitored; (3) western blot is used for detecting the expression conditions of HIF-1 alpha and VEGF related proteins of an HIF-1 alpha signal pathway; expression levels of synaptic related proteins CaMK ii, PSD95, and CRBE. Thereby determining the effect of the roxasistat on synaptic plasticity damage mediated by cerebral arterial ischemic reperfusion. The specific grouping is as follows:
2. experimental methods
2.1 construction of Central cerebral artery embolism (MCAO) reperfusion injury model
One end of a nylon wire with the diameter of 0.23mm is repeatedly immersed into the molten paraffin for about 5 times, and after the paraffin on the surface of the nylon wire is solidified, the suppository wire is immersed into the heparin for 30min and then dried for later use. After anesthetizing (0.35mL/100g) rats by intraperitoneal injection of 10% chloral hydrate, they were fixed supine on the operating table with the rubber band, and the median incision of the neck was taken, the fascia was cut, the right sternocleidomastoid muscle and sternohyoid muscle were blunt-isolated, and the right Common Carotid Artery (CCA) and vagus nerve were exposed and isolated. The ECA, ICA were isolated and the ECA was ligated along the bifurcation of the right External Carotid Artery (ECA) and Internal Carotid Artery (ICA). Clamping the CCA and the ICA by using an artery clamp, cutting a small opening at a position 5mm away from the artery bifurcation of the ECA by using an ophthalmic scissors, slowly inserting the thread plug into the ICA, removing the ICA artery clamp when the ICA and the ECA are intersected, adjusting the thread plugging angle, continuously and slowly pushing the thread plug towards the ICA cranium direction until the insertion depth is 18 +/-0.5 mm. Ligating and fixing the thread with ECA, loosening the CCA artery clamp, cutting off the redundant tail end of the thread bolt, and finally suturing fascia and skin. After 2h of ischemia, the suppository was withdrawn, the ECA proximal bifurcation was ligated, and the Sham group (Sham group) was operated in the same manner as the model group except that no insertion was performed.
2.2 Experimental treatment
Performing different treatments according to the groups, namely, constructing a model with right cerebral ischemia for 2h and reperfusion for 7 days by using a sham operation group with only the cervical artery exposed and no inserting wire for molding, constructing a model group with right cerebral ischemia for 2h, constructing a positive control group, performing edaravone treatment on a model rat according to 5mg/kg after molding, preparing a low-dose group of rosmarinstat according to 10mg/kg after molding, performing rosmarinstat treatment on a model rat according to 10mg/kg after molding, and preparing a high-dose group of rosmarinstat according to 20mg/kg after molding.
2.3 rat brain tissue fixation
The rats are anesthetized by intraperitoneal injection of 10% chloral hydrate, the thoracic cavity is opened, the rats are fixed by cardiac perfusion of 4% paraformaldehyde for 15min, then the rats are perfused by normal saline for 10min, brain tissues are taken out, and the rats are continuously soaked in the 4% paraformaldehyde for 24h and can be used for paraffin embedding sections.
2.4 TTC staining
After the model is made for 24 hours, anesthetizing a rat, taking the brain, freezing for 30min at the temperature of-20 ℃, continuously cutting the rat brain into coronal sections from the frontal pole to the back, cutting a layer by about 2mm, placing the brain slice into a 1% TTC solution, incubating for 20min at 37 ℃ in a dark place, then placing the brain slice into a 4% paraformaldehyde solution for fixing for 24 hours, and scanning by a scanner to obtain an image. Normal brain tissue appears bright red, and infarcted brain tissue appears white. The infarct area and total area of each tablet were measured by Image J software, and the infarct volume in each layer was the infarct area x the layer thickness, and the total infarct volume was the sum of the infarct volumes in each layer. Infarct volume percentage infarct area volume/total brain volume x 100%.
As shown in fig. 1, rosxastat can significantly reduce the volume of cerebral infarction mediated by ischemic stroke reperfusion and control mortality.
2.5 HE staining
The paraffin sections were baked in a thermostat at 60 ℃ for 1 h. Dewaxing and hydrating: xylene 2 × 15min → absolute ethanol 2 × 5min → 90% ethanol 5min → 70% ethanol 5min → 50% ethanol 5min → distilled water 5 min; and (3) carrying out hematoxylin nuclear staining: hematoxylin staining for 5-10min (the specific time can be adjusted according to different tissue staining results and requirements) → recovering the staining solution, washing with tap water until the section turns blue → separating with 1% hydrochloric acid and alcohol solution for color separation, removing the excess staining solution → washing with tap water; eosin staining: placing the slices into 1% eosin solution for infection for 5-10 min; and (3) dehydrating and transparency: ddH2O washed off eosin dye solution → 70%, 80%, 90% ethanol for color separation and dehydration, 5min → absolute ethanol 2X 3min → xylene 2X 3min each time; sealing with neutral gum, and storing at room temperature for a long time.
The results are shown in fig. 2, and the results show that the roxasistat can reduce the apoptosis number of nerve cells and remarkably relieve the damage caused by cerebral arterial thrombosis reperfusion.
2.6 Western blot detection
(1) Extraction of total tissue protein
1) Taking about 50-100mg of ischemic lateral cortex brain tissue, putting the ischemic lateral cortex brain tissue into a homogenizer, adding 200-400uLRIPA lysate (containing a phosphatase inhibitor), and homogenizing the slurry in ice bath until no large-particle precipitate exists. The homogenate was transferred to a 1.5mLEP tube, incubated in an ice bath for about 15min for complete lysis, transferred to a cryo-centrifuge and centrifuged at 12000rpm for 5 min.
2) And (3) subpackaging the protein supernatant into 0.5mLEP tubes, and storing in a refrigerator at-20 ℃.
(2) Measurement of tissue protein content (BCA method)
1) Diluting a protein standard (5mg/mL) by 10 times by using RIPA lysate, namely adding 10uL of the protein standard into 90uL of RIPA lysate, adding the diluted protein standard into a 96-well plate according to the proportion of 0uL, 1uL, 2uL, 4uL, 8uL, 12uL, 16uL and 20uL, and then supplementing the solution to 20uL per well by using the RIPA lysate.
2) 19uLRIPA lysate was added to 96-well plates, and 1uL of the protein of interest was added, and triplicate wells were assayed for each sample.
3) Preparing a BCA working solution: according to the formula of the solution A: and preparing solution B at a ratio of 50:1, adding 200uL of BCA working solution into each hole, and then placing in an incubator at 60 ℃ for 30 min.
4) OD572 is measured by a microplate reader, a standard curve is drawn, and the concentration of the target protein is calculated.
(3) Western Blot analysis
1) Preparing loading protein: taking 6 mu L of protein Sample to be detected (50 mu g) and SDS Reducing Sample Buffer (5 x) to an EP tube, supplementing RIPA lysate to a 30 mu L system, vortex, shaking, mixing uniformly, carrying out water bath at 95 ℃ for 5min to denature the protein, cooling to room temperature, and storing at-20 ℃ for later use.
2) Preparing glue: preparing 12% separation gel: 30% Acrylamide mix 8mL, 1.5M Tri HCl (pH 8.8): 5mL, ddH 2O: 6.6mL, 10% SDS: 0.2mL, 0.2mL of 10% APS, TEMED; 0.008 mL. Mixing, pouring into a glass plate for gel making, flattening the liquid surface with 1ml ddH2O, and gelling at room temperature for 60 min.
3) Preparing 5% concentrated glue: 30% Acrylamide mix 1mL, 1M Tri HCl (pH 6.8): 0.75mL, ddH 2O: 4.1mL, 10% SDS: 0.06mL, 0.06mL of 10% APS, and 0.01mL of TEMED. Pouring off water on the separation gel, sucking dry with filter paper, adding concentrated gel, inserting into comb with 5mm aperture, gelling at room temperature for 40min, and taking out the comb after the concentrated gel is formed.
4) Electrophoresis: the gel plate was placed in a vertical electrophoresis tank, electrophoresis buffer was poured in, and the prepared loading protein and MAKER were sampled by a microsyringe into loading wells at 25. mu.l per well. And (5) carrying out constant-voltage 100V electrophoresis until bromophenol blue is specially moved to the bottom of the separation gel, and stopping electrophoresis.
5) Electrotransfer: and (3) cutting the PVDF membrane and the filter paper with the same size as the separation gel, firstly soaking the PVDF membrane in methanol for several seconds, then soaking the PVDF membrane and the filter paper in the electric transfer liquid, clamping the PVDF membrane and the filter paper by an electric transfer clamp (the PVDF membrane is close to a white plate) in the sequence of the filter paper-the PVDF membrane-the separation gel-the filter paper, putting the PVDF membrane and the filter paper into an electric transfer groove, pouring the electric transfer liquid, and carrying out 350mA constant current electric transfer in an ice bath for about 75 minutes.
6) Blocking and incubating the antibody: immersing the PVDF membrane in 5% skimmed milk powder, and sealing for 2h in a shaking table at room temperature; pouring off the blocking solution, adding primary antibody diluted with the blocking solution, incubating at 4 deg.C overnight, incubating at room temperature for 30min the next day, recovering the primary antibody, and storing at-20 deg.C. Washing the membrane with TBST for 3 × 10min, adding HRP secondary antibody diluted by blocking solution, incubating for 2h at room temperature in a shaking table, and washing with TBST for 3 × 10 min.
7) Developing and exposing: uniformly mixing a stable peroxidase solution and an enhancement solution in an ECL luminescent reagent according to the volume ratio of 1:1, dripping the mixture onto a PVDF membrane, removing redundant luminescent substrates after reaction for a plurality of minutes to obviously emit light, wrapping the luminescent substrates with a preservative film, tabletting and exposing an X-ray film, washing the film with a developing solution and a fixing solution, drying the film, and scanning by a scanner.
8) And analyzing the gray value of the film by using Image J software, and calculating the relative content of the target protein by using the ratio of the target protein to the internal reference beta-actin.
The results are shown in fig. 3 and fig. 4, and it can be seen that the rosxastat can significantly increase the expression of HIF-1 α, VEGF, CaMK ii, PSD95 and CRBE, which indicates that the rosxastat can alleviate ischemic stroke reperfusion-mediated neurosynaptic injury by regulating the expression of synapse-related protein on the basis of regulating the activity of HIF-1 α pathway.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (2)
1. Application of roxasistat in medicines for treating cerebral arterial thrombosis reperfusion-mediated synaptic injury.
2. Use according to claim 1, characterized in that:
the dosage of the roxasistat is 10 mg/kg-20 mg/kg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111323576.8A CN113813260A (en) | 2021-11-10 | 2021-11-10 | Use of roxasistat for relieving ischemic stroke-mediated synaptic injury |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111323576.8A CN113813260A (en) | 2021-11-10 | 2021-11-10 | Use of roxasistat for relieving ischemic stroke-mediated synaptic injury |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113813260A true CN113813260A (en) | 2021-12-21 |
Family
ID=78919259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111323576.8A Pending CN113813260A (en) | 2021-11-10 | 2021-11-10 | Use of roxasistat for relieving ischemic stroke-mediated synaptic injury |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113813260A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114470159A (en) * | 2022-02-23 | 2022-05-13 | 武汉科技大学 | Application of Spag6 in preparation of medicine for relieving synapse damage mediated by cerebral arterial thrombosis reperfusion |
CN114763529A (en) * | 2022-05-23 | 2022-07-19 | 温州医科大学附属第一医院 | Application of roxasistat in enhancing survival capability of BMSCs in ischemic environment |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101420980A (en) * | 2006-02-16 | 2009-04-29 | 菲布罗根公司 | The Compounds and methods for of treatment apoplexy |
CN108451954A (en) * | 2018-02-02 | 2018-08-28 | 中国人民解放军军事科学院军事医学研究院 | The new application and drug and health products of FG-4592 or its salt |
WO2019148471A1 (en) * | 2018-02-02 | 2019-08-08 | 中国人民解放军军事科学院军事医学研究院 | Novel use, medicament and health supplement using fg-4592 or salt thereof |
-
2021
- 2021-11-10 CN CN202111323576.8A patent/CN113813260A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101420980A (en) * | 2006-02-16 | 2009-04-29 | 菲布罗根公司 | The Compounds and methods for of treatment apoplexy |
CN108451954A (en) * | 2018-02-02 | 2018-08-28 | 中国人民解放军军事科学院军事医学研究院 | The new application and drug and health products of FG-4592 or its salt |
WO2019148471A1 (en) * | 2018-02-02 | 2019-08-08 | 中国人民解放军军事科学院军事医学研究院 | Novel use, medicament and health supplement using fg-4592 or salt thereof |
Non-Patent Citations (4)
Title |
---|
AYESHA SINGH等: "Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model", 《SCIENTIFIC REPORTS》 * |
GAIFEN LI等: "FG-4592 Improves Depressive-Like Behaviors through HIF-1-Mediated Neurogenesis and Synapse Plasticity in Rats", 《NEUROTHERAPEUTICS》 * |
JUN LI等: "HIF‑1α attenuates neuronal apoptosis by upregulating EPO expression following cerebral ischemia‑reperfusion injury in a rat MCAO model", 《INT J MOL MED》 * |
张敏主编: "《神经病学临床与康复》", 31 May 2020, 黑龙江科学技术出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114470159A (en) * | 2022-02-23 | 2022-05-13 | 武汉科技大学 | Application of Spag6 in preparation of medicine for relieving synapse damage mediated by cerebral arterial thrombosis reperfusion |
CN114763529A (en) * | 2022-05-23 | 2022-07-19 | 温州医科大学附属第一医院 | Application of roxasistat in enhancing survival capability of BMSCs in ischemic environment |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113813260A (en) | Use of roxasistat for relieving ischemic stroke-mediated synaptic injury | |
Kanno et al. | Spinal cord injury induces upregulation of Beclin 1 and promotes autophagic cell death | |
Peng | TRPV5 and TRPV6 in transcellular Ca 2+ transport: regulation, gene duplication, and polymorphisms in African populations | |
Liu et al. | BDNF‐TrkB pathway mediates antidepressant‐like roles of H2S in diabetic rats via promoting hippocampal autophagy | |
Gutierrez et al. | The puerperium alters spinal cord plasticity following peripheral nerve injury | |
Handa et al. | Evidence that serotonin is involved in the sexually dimorphic development of the preoptic area in the rat brain | |
CN103405408B (en) | The application of chrysin in treatment ischemic cerebral apoplexy Chinese medicine | |
Schaffer et al. | The ontogenies of endometrial and myometrial leptin and adiponectin receptors in pregnant rats: Their putative impact on uterine contractility | |
Zhao et al. | BIO alleviates inflammation through inhibition of GSK-3β in a rat model of intracerebral hemorrhage | |
Mason et al. | Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells | |
Wang et al. | Endogenous nitric oxide regulates blood vessel growth factors, capillaries in the cortex, and memory retention in Sprague-Dawley rats | |
Russo et al. | The windows of susceptibility to breast cancer | |
Zhang et al. | Effect of manganese on heat stress protein synthesis of new-born rats | |
CN113350358B (en) | Application of tenuigenin single or combined with hydroxysafflor yellow A in preparation of medicine for improving cognitive impairment after ischemic stroke | |
CN109125331A (en) | GABABApplication of the receptor antagonist in terms of blocking the channel TREK-1 | |
Wang et al. | Puerarin Up-regulates Methyl-CpG binding protein 2 phosphorylation in hippocampus of vascular dementia rats | |
Ajonuma et al. | Prolonged Ingestion of Crude Oil Spill Contaminated Water Affects Male Reproductive System, Hormones and Accessory Organs in Wistar rats | |
CN104622931A (en) | Application of eight-component pill in preparation of medicine for preventing or treating cerebral ischemia and its complication | |
CN108714146A (en) | A kind of ferulic acid pharmaceutical composition and its new application | |
Kirubagaran et al. | Changes in verte brate‐type steroids and 5‐hydroxytryptamine during ovarian recrudescence in the Indian spiny lobster, Panulirus homarus | |
CN109091479B (en) | Application of guanfu base A in preparation of medicine for treating neuropathic pain | |
CN115770242B (en) | Application of sorafenib in preparing medicament for treating growth hormone dyssecretion after cerebral hemorrhage | |
CN114796187B (en) | Application of hydroxysafflor yellow A in preparation of medicine for treating adenomyosis | |
Liu et al. | Electroacupuncture alleviates intrauterine adhesion through regulating autophagy in rats | |
Brown-Grant et al. | Lack of effect of pineal denervation on the responses of the female albino rat to exposure to constant light |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211221 |